Market Place
Sourcing Support
Photocure Partner Asieris Unveils Cevira Ph 3 Analysis By Age
30 Sep 2024 //
PR NEWSWIRE
Asieris Releases 2024 Semi-Annual Report, Highlights Product Progress
28 Aug 2024 //
PR NEWSWIRE
ReviR Reaches Milestone In Splicing Therapy Development With Asieris
17 Jun 2024 //
PR NEWSWIRE
Asieris Pharmaceuticals Unveils 2023 Annual Report
17 Apr 2024 //
PR NEWSWIRE
Photocure Partner Asieris announces positive Phase III trial results for Cevira
18 Mar 2024 //
PR NEWSWIRE
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion
18 Mar 2024 //
PR NEWSWIRE
Asieris Releases Phase III Study and Real-World Research Data for APL-1706
29 Jan 2024 //
PR NEWSWIRE
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202
25 Jan 2024 //
PR NEWSWIRE
Asieris Pharma Appoints Sophia Cao to Lead the Women`s Health Business Unit
08 Jan 2024 //
PR NEWSWIRE
APL-2301 was approved for Phase I clinical trials in Australia
24 Dec 2023 //
PR NEWSWIRE
Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706
12 Oct 2023 //
PR NEWSWIRE
Asieris` New Drug APL-1401 Completes First Administration in Patient
14 Sep 2023 //
PR NEWSWIRE
Asieris Obtained IND Approval from NMPA for APL-1401, a Drug
30 Aug 2023 //
PR NEWSWIRE
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report
22 Aug 2023 //
PR NEWSWIRE
Asieris Announces Positive Phase III Bridging Trial of Hexvix
11 Aug 2023 //
PR NEWSWIRE
Hexvix A Diagnostic Drug for Bladder Cancer of Asieris has Completed PhIII trial
06 Jul 2023 //
PR NEWSWIRE
Asieris Deepens Strategic Partnership with UroViu
18 May 2023 //
PR NEWSWIRE
Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Devp
17 Apr 2023 //
PR NEWSWIRE
Asieris` subsidiary makes progress by obtaining the "Drug Distribution License"
10 Apr 2023 //
PR NEWSWIRE
NMPA accepted the registration applications for Uro-G and Uro-3500
21 Feb 2023 //
PR NEWSWIRE
ReviR and Asieris Enter into Agreement to Discover Oncology Therapeutics
08 Feb 2023 //
PR NEWSWIRE
Asieris Pharma appoints Dr Linda Wu as Chief Development Officer
19 Jan 2023 //
BIOSPECTRUM ASIA
Asieris Appoints Dr. Linda Wu as Chief Development Officer
17 Jan 2023 //
PR NEWSWIRE
Asieris enrols first subject in Phase II bladder cancer therapy trial
14 Dec 2022 //
CLINICALTRIALSARENA
Asieris`Bladder Cancer Diagnostic Drug Hexvix Completed Dosing of First Patient
12 Dec 2022 //
PRNEWSWIRE
Asieris Enrolled First Patient for PII Study of Oral APL-1202 with Tislelizumab
12 Dec 2022 //
PRNEWSWIRE
US FDA approves Asieris Pharma’s IND application for oral drug APL-1401
11 Nov 2022 //
PHARMABIZ
Asieris Obtained IND Approval from US FDA for APL-1401
10 Nov 2022 //
PRNEWSWIRE
Hexvix Completed the First Patient Dose in Phase III Trial
06 Nov 2022 //
PRNEWSWIRE
Hexvix is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
15 Sep 2022 //
PRNEWSWIRE
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
29 Aug 2022 //
BUSINESSWIRE
Asieris Pharma Issued 2022 Semi-Annual Report
24 Aug 2022 //
PRNEWSWIRE
Asieris completes enrollment in phase III trial of Cevira
10 Aug 2022 //
PHARMABIZ
Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board
10 Aug 2022 //
PR NEWSWIRE
Asieris to present study protocol of APL-1202 with BeiGene`s tislelizumab
27 May 2022 //
PRNEWSWIRE
Asieris Pharmaceuticals Announces 2021 Annual Report
14 Apr 2022 //
PRNEWSWIRE
Hexvix Obtains CDE Approval for Inclusion In Real-world Evidence Pilot Study
14 Mar 2022 //
PRNEWSWIRE
Asieris announces CDE Approval for Hexvix Clinical Real-World Evidence Study
11 Mar 2022 //
PRNEWSWIRE
Asieris to Increase Presence at ASCO GU 2022
16 Feb 2022 //
PRESS RELEASE
World`s 1st Patient Dose Given in Comb. of APL-1202 & Tislelizumab in MIBC
04 Jan 2022 //
ASIAONE
The CDE Approved IND Application to Investigate Combination of Asieris` APL-1202
13 Oct 2021 //
PRNEWSWIRE
Asieris Announces First Patient Treated in Europe in APRICITY
22 Jun 2021 //
PRNEWSWIRE
Asieris Announces First Patient Treated in Europe in APRICITY Trial of Cevira®
21 Jun 2021 //
PRNEWSWIRE
BeiGene, Asieris ink collaboration to evaluate safety and oral APL-1202
07 May 2021 //
PHARMABIZ
Asieris and BeiGene Enter into Clinical Collaboration to Evaluate of APL-1202
06 May 2021 //
PRNEWSWIRE
Asieris and BeiGene Enter into Clinical Collaboration to Evaluate of APL-1202
06 May 2021 //
PRNEWSWIRE
Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis
26 Jan 2021 //
PRNEWSWIRE
Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis
26 Jan 2021 //
BIOSPACE
Asieris Announces First Patient Adm in the Global Ph III Trial for APL-1702
11 Nov 2020 //
PRNEWSWIRE
Asieris Announces First Patient Admin in the Global Ph III Trial for APL-1702
11 Nov 2020 //
BIOSPACE
Asieris Announces First Patient Administration in the Global PhIII for APL-1702
10 Nov 2020 //
PRNASIA
Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent
04 Nov 2020 //
PRNEWSWIRE
Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent
04 Nov 2020 //
PRNASIA
Asieris` APL-1501 Approved for Phase I Clinical Trial in Australia
30 Oct 2020 //
PRNEWSWIRE
Asieris announces approval for Ph 1 trial of bladder cancer drug in Australia
30 Oct 2020 //
BIOSPECTRUMASIA
